Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Lb Pharmaceuticals Inc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Lb Pharmaceuticals Inc (LBRX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/LBRX/competitors
https://api.csimarket.com/api/v1/companies/LBRX/relationships
https://api.csimarket.com/api/v1/companies/LBRX/similar
Programmatic access for models, analytics, and integration workflows.

Lb Pharmaceuticals Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Lb Pharmaceuticals Inc - - - -
Similar-Size Competitors (9) 20% 75% 50% 29%

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

LBRX Stock Performance relative to its Competitors

LBRX Competitors (weighted) Percent change over the selected range

Lb Pharmaceuticals Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.
44.4%beat U.S.A. 500
Similar-Size
(4 of 9)
Entity TTM Share Price Return
(group: median)
vs U.S.A. 500
Lb Pharmaceuticals Inc 146.40 % Outperformed
Competitors combined (0) 40.4% 63.2%
High-Confidence Competitors (0) 40.4% 63.2%
Similar-Size Competitors (9) 40.4% 63.2%
Similar Growth & Profitability (0) 40.4% 63.2%
Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Lb Pharmaceuticals Inc's competitor groups requires a Commercial License.

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

LBRX Stock Performance relative to Similar-Size Competitors

LBRX Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Lb Pharmaceuticals Inc's Comment on Competition and Industry Peers

The company operates in a competitive environment that includes biopharmaceutical and biotechnology firms developing therapeutics for schizophrenia, as well as academic institutions, governmental agencies, and public and private research organizations. Several competitors possess greater financial resources and comparable or more extensive experience in drug discovery, development, and regulatory approval. The industry is marked by rapid innovation and intense competition. The company's lead product candidate is LB-102, which is under development for neuropsychiatric diseases.
Competitor data is not yet available for Lb Pharmaceuticals Inc.
Get the full CSIMarket dataset: Subscribe API License